Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
Identifieur interne : 002225 ( Main/Exploration ); précédent : 002224; suivant : 002226Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-03-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Comparative study, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans (administration & dosage), Levodopa (therapeutic use), Long term, Longitudinal Studies, MAO‐B inhibitor, Male, Middle Aged, Modification, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine oxidase B inhibitor, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Prognosis, Quality of Life, Rasagiline, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment, Treatment Outcome, disease modification, neuroprotection, rasagiline, treatment.
- MESH :
- chemical , administration & dosage : Indans, Monoamine Oxidase Inhibitors.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Middle Aged, Quality of Life, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22402
Affiliations:
- Israël, États-Unis
- Californie, Floride, Indiana, Pennsylvanie, Texas
- Tampa
- Université de Floride du Sud
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000327
- to stream Istex, to step Curation: 000327
- to stream Istex, to step Checkpoint: 000E27
- to stream PubMed, to step Corpus: 001F10
- to stream PubMed, to step Curation: 001F10
- to stream PubMed, to step Checkpoint: 001D33
- to stream Ncbi, to step Merge: 002455
- to stream Ncbi, to step Curation: 002455
- to stream Ncbi, to step Checkpoint: 002455
- to stream Main, to step Merge: 002A86
- to stream PascalFrancis, to step Corpus: 000F47
- to stream PascalFrancis, to step Curation: 001D72
- to stream PascalFrancis, to step Checkpoint: 000E20
- to stream Main, to step Merge: 002F17
- to stream Main, to step Curation: 002225
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</author>
<author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22402</idno>
<idno type="url">https://api.istex.fr/document/5B1103AD18D631B83CB2914DC8D246159F83891D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000327</idno>
<idno type="wicri:Area/Istex/Curation">000327</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E27</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:long:term:outcome</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19086083</idno>
<idno type="wicri:Area/PubMed/Corpus">001F10</idno>
<idno type="wicri:Area/PubMed/Curation">001F10</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001D33</idno>
<idno type="wicri:Area/Ncbi/Merge">002455</idno>
<idno type="wicri:Area/Ncbi/Curation">002455</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002455</idno>
<idno type="wicri:Area/Main/Merge">002A86</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0171575</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F47</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D72</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000E20</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hauser R:long:term:outcome</idno>
<idno type="wicri:Area/Main/Merge">002F17</idno>
<idno type="wicri:Area/Main/Curation">002225</idno>
<idno type="wicri:Area/Main/Exploration">002225</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Keck/University of Southern California School of Medicine, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana</wicri:regionArea>
<placeName><region type="state">Indiana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Teva Pharmaceutical Industries Ltd, Petach Tikva</wicri:regionArea>
<wicri:noRegion>Petach Tikva</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-03-15">2009-03-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="564">564</biblScope>
<biblScope unit="page" to="573">573</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5B1103AD18D631B83CB2914DC8D246159F83891D</idno>
<idno type="DOI">10.1002/mds.22402</idno>
<idno type="ArticleID">MDS22402</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Comparative study</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Indans (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Long term</term>
<term>Longitudinal Studies</term>
<term>MAO‐B inhibitor</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Modification</term>
<term>Monoamine Oxidase Inhibitors (administration & dosage)</term>
<term>Monoamine oxidase B inhibitor</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Prognosis</term>
<term>Quality of Life</term>
<term>Rasagiline</term>
<term>Reproducibility of Results</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>disease modification</term>
<term>neuroprotection</term>
<term>rasagiline</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indans</term>
<term>Monoamine Oxidase Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Quality of Life</term>
<term>Reproducibility of Results</term>
<term>Retrospective Studies</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etude comparative</term>
<term>Inhibiteur de la monoamine oxidase B</term>
<term>Long terme</term>
<term>Maladie de Parkinson</term>
<term>Modification</term>
<term>Pathologie du système nerveux</term>
<term>Pronostic</term>
<term>Rasagiline</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this study to compare the long‐term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early‐start group) or placebo for 6 months followed by rasagiline (delayed‐start group) in the TEMPO study. Subjects who chose to participate in an open‐label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (±SD) duration in the study was 3.6 ± 2.1 years; 177 subjects received rasagiline for ≥5.0 years. Over the entire 6.5‐year follow‐up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early‐start versus delayed‐start rasagiline group. Although the interaction between treatment and time was significant, values for the early‐start group were better than the delayed‐start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early‐start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Israël</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Indiana</li>
<li>Pennsylvanie</li>
<li>Texas</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I." last="Hurtig">Howard I. Hurtig</name>
<name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F." last="Lew">Mark F. Lew</name>
<name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name>
</country>
<country name="Israël"><noRegion><name sortKey="Fitzer Ttas, Cheryl J" sort="Fitzer Ttas, Cheryl J" uniqKey="Fitzer Ttas C" first="Cheryl J." last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:5B1103AD18D631B83CB2914DC8D246159F83891D |texte= Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |